51 results about "Myofibrosis" patented technology

The invention provides a polypeptide. The amino acid sequence of the polypeptide is shown as SEQ ID NO. 1. Specifically, the sequence of the polypeptide is as follows: MTSRQEDASGKKTTEGAKFQGS. The invention also provides a DNA (deoxyribonucleic acid) molecule for coding the polypeptide according to the claim 1. The invention also provides a recombinant vector containing the DNA molecule. The invention also provides application of the polypeptide in preparation of medicines for treating myocardial fibrosis. The invention further provides a pharmaceutical composition, and the effective component of the pharmaceutical composition is the polypeptide. Experiments prove that the traditional Chinese medicine can relieve myocardial fibrosis.

The invention discloses application of piperlongumine in preparation of a medicine for treating virus-induced myocardial fibrosis. According to the application, an in-vivo myocardial fibrosis model is constructed by infecting a BALB / c mouse with a CVB3 virus, and meanwhile, an in-vitro cell model for proliferation and differentiation of primary myocardial fibroblasts is constructed by inducing TGF-beta1. Results prove that when the piperlongumine is applied to the acute stage (1-14 days), the chronic stage (14-28 days) and the whole course (1-28 days) of the viral myocarditis, the myocardial fibrosis of the viral myocarditis can be remarkably improved, the cardiac function is improved, and the curative effect of the piperlongumine applied to the whole course is superior to that of the piperlongumine applied to the acute stage and the chronic stage; the specific mechanism is that Smad2 / 3 and p-38 / YAP pathways jointly play a role in inhibiting myocardial fibrosis.

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Connexin43 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to define the effect of connexin43 in the cardiac hypertrophy process caused by myocardial cell hypertrophy induced by pathological matrix stiffness and pressure overload, the invention provides application of an inhibitor of a targeted Connexin43 gene in preparation of a medicine for preventing or treating myocardial fibrosis. According to the application disclosed by the invention, the Connexin43 gene is found to be used as a potential target for preventing or treating myocardial fibrosis for the first time, and a myocardial cell hypertrophy process induced by pathological matrix hardness and a myocardial hypertrophy process caused by overload of pressure can be relieved by knocking down the expression of the Connexin43 gene or inhibiting the semi-channel activity of the Connexin43. Therefore, the inhibitor targeting the Connexin43 gene can be used for preparing the medicine for preventing or treating the myocardial fibrosis, and a new way is provided for treating the myocardial fibrosis.

The invention belongs to the technical field of biological medicines, and particularly provides a small molecule compound E229-0305 for preparing a medicine for treating myocardial fibrosis. The small molecule compound E229-0305 can target PTGS2 protein, inhibit fibrosis of myocardial fibroblasts induced by TGF-beta1, reduce proliferation and migration capabilities of the myocardial fibroblasts, inhibit the fibroblasts from being converted into myofibroblasts, and inhibit expression of fibrosis-related genes and proteins. Besides, in a model of myocardial fibrosis after myocardial infarction of a mouse, the small molecule compound E229-0305 improves the cardiac function of the mouse with myocardial infarction and reduces the fibrosis area and collagen deposition of the heart. The small molecule compound E229-0305 can be used as a brand-new targeted PTGS2 small molecule inhibitor for preparing medicines for preventing and treating myocardial fibrosis.

This invention provides a polypeptide whose amino acid sequence is shown in SEQ ID NO.1. Specifically, the sequence of the polypeptide is: MTSRQEDASGKKTTEGAKFQGS. This invention also provides a DNA molecule encoding the polypeptide of claim 1. This invention further provides a recombinant vector containing the above-mentioned DNA molecule. This invention also provides the use of the above-mentioned polypeptide in the preparation of a medicament for treating myocardial fibrosis. This invention also provides a pharmaceutical composition in which the above-mentioned polypeptide is the active ingredient. Experiments have shown that this invention can alleviate myocardial fibrosis.

The invention belongs to the technical field of medicines, and particularly relates to application of indole-3-propionic acid in preparation of a medicine for treating myocardial ischemia-reperfusion injury. A stable and reliable mouse MIRI model is successfully constructed through a coronary artery ligation left anterior descending branch reperfusion method, and it is found through indole-3-propionic acid (IPA) intervention and multi-dimensional evaluation that IPA administration can significantly improve the left ventricular ejection fraction LVEF and the left ventricular short-axis shortening rate LVFS of a model mouse, reduce the left ventricular end diastolic inner diameter LVEDd and the end systolic inner diameter LVESd, and significantly improve the model mouse left ventricular ejection fraction LVEF, the left ventricular end diastolic inner diameter LVEDd and the left ventricular end diastolic inner diameter LVESd. The heart function is effectively improved; the myocardial fibrosis area can be reduced, the mRNA expression of fibrosis-promoting and pathological hypertrophy-promoting molecules in myocardial tissues can be obviously reduced, and the myocardial injury progress can be inhibited in a multi-dimensional manner. The invention provides a brand new strategy for treating myocardial ischemia reperfusion injury, has important application value and wide clinical transformation prospect, and is expected to provide a new direction for clinical treatment.

The invention discloses a diagnosis marker for diabetes complicated with atrial fibrillation and application of the diagnosis marker, and relates to the technical field of biological medicine. The diagnostic marker is hematopoietic cell kinase (HCK). The invention finds that HCK can effectively predict the occurrence risk of diabetes mellitus combined with atrial fibrillation and provide an effective treatment target for diabetes mellitus combined with atrial fibrillation. The invention verifies that the knock-down HCK can effectively inhibit AGEs-induced HL-1 cell CaMKII phosphorylation, myocardial fibrosis, mitochondrial membrane potential damage and ROS generation, and alleviates the inhibition effect on AMPK / mTOR signal channel activation, thereby reducing the atrial fibrillation susceptibility. The invention also proves that the risk (AUC is 0.853) of the diabetic with atrial fibrillation can be accurately identified by detecting the HCK level in the plasma. The invention provides a new medical approach for early risk assessment and targeted intervention of diabetes mellitus combined with atrial fibrillation.

The invention discloses an application of a disulfiram medicine in improving sepsis induced cardiomyopathy. The disulfiram drug is administered in a sepsis mouse model, and the disulfiram drug is proved to have obvious anti-inflammatory effect and myocardial protection effect. The disulfiram medicine can relieve myocardial hypertrophy of mice, relieve the degree of myocardial fibrosis and reduce myocardial interstitial inflammatory exudation, ZO-1 reconstructs continuous linear distribution after administration, and the degree of myocardial edema is obviously relieved. The invention provides a new application of the disulfiram medicine in improving sepsis-induced cardiomyopathy, and provides a new strategy for myocardial protection of sepsis.

The present application relates to the technical field of biological medicine, in particular to application of aconitum brachypodum franch alcohol extract in myocardial protection, and discloses that the aconitum brachypodum franch alcohol extract mainly inhibits formation of myocardial fibrosis, reduces inflammatory reaction and reduces cell apoptosis by adjusting a TLR4 / MyD88 / NF-kappa B channel, thereby protecting ISO-induced myocardial injury of a mouse; the present application provides a theoretical basis for improving myocardial injury by the aconitum brachypodum franch, and also provides a scientific basis for development and utilization of the aconitum brachypodum franch.

The application belongs to the field of biological medicine, and relates to an anti-mouse integrin CD103 nanobody and application. The anti-mouse integrin CD103 nanobody comprises three complementarity determining regions CDR1, CDR2 and CDR3; wherein the amino acid sequence of CDR1 is a sequence or a high homology sequence shown in one of SEQ ID NO:1 to SEQ ID NO:4, the amino acid sequence of CDR2 is a sequence or a high homology sequence shown in one of SEQ ID NO:5 to SEQ ID NO:8, and the amino acid sequence of CDR3 is a sequence or a high homology sequence shown in one of SEQ ID NO:9 to SEQ ID NO:12. The application relates to the anti-mouse integrin CD103 nanobody and a preparation method thereof 18 The F-CYNB nanobody probe can realize targeted imaging of myocardial fibrosis, immune imaging of mouse tumors, and prediction of the effect of tumor immunotherapy.

The invention belongs to the field of biological medicine, and particularly relates to a traditional Chinese medicine composition for treating heart yin deficiency and myocardial fibrosis and application thereof. The traditional Chinese medicine composition is prepared from the following raw medicinal materials in parts by weight: 5-13 parts of lily, 5-13 parts of radix ophiopogonis, 3-9 parts of ginseng, 5-13 parts of radix scrophulariae, 3-9 parts of semen boitae and 1-5 parts of schisandra chinensis. The invention also provides a preparation method of the composition. The composition has the effects of reinforcing qi, nourishing yin, calming the heart and tranquilizing the mind, and can be used for preparing medicines for treating heart-yin deficiency and myocardial fibrosis or improving heart-yin deficiency symptoms. Experimental results show that the traditional Chinese medicine composition can significantly improve the heart function of a chronic heart failure model mouse, inhibit myocardial cell hypertrophy and collagen deposition, and down-regulate fibrosis-related gene expression. Clinical observation shows that the traditional Chinese medicine can effectively relieve the symptoms of palpitation, insomnia, dysphoria with smothery sensation and the like of patients with heart yin deficiency. The traditional Chinese medicine composition is clear in formula and controllable in quality, and a novel safe and effective traditional Chinese medicine choice is provided for treating heart yin deficiency related myocardial fibrosis.

The application discloses application of a composition containing tanshinone extract and muscone, and belongs to the technical field of medicines. The compatibility and ratio control of the tanshinone extract and the muscone can inhibit expression and / or secretion of FSTL1 of cardiac fibroblasts at a molecular level, regulate related fibrosis signal pathways, thereby inhibiting a myocardial fibrosis process, and producing a synergistic effect with anti-myocardial injury, improving ventricular structure and function abnormalities after myocardial infarction, and being used for treating cardiovascular diseases such as myocardial infarction, myocardial fibrosis and heart failure after myocardial infarction. The composition of the application comprises the tanshinone extract and the muscone, and can be used for preparing a medicine for preventing and treating cardiovascular diseases with better effects.

The application belongs to the technical field of biological medicine, and particularly relates to a use of Serpine1 gene as a target in preparation of a drug for preventing or treating myocardial fibrosis. In order to screen key molecules for intervention and regulation of extracellular matrix balance, and provide a basis for development of a drug for preventing or treating myocardial fibrosis, the application determines important functions of Serpine1 in myocardial fibrosis through experiments, and provides a use of Serpine1 gene as a target in preparation of a drug for preventing or treating myocardial fibrosis. The application verifies through experiments that knocking down expression of Serpine1 can improve impaired cardiac systolic function caused by thoracic aortic arch constriction for 4 weeks, reduce myocardial fibrosis, and inhibit activation of myocardial fibroblasts, and can be used for preparation of a drug for preventing or treating myocardial fibrosis, and has important practical significance.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition for improving heart failure and its preparation method. The traditional Chinese medicine composition for improving heart failure comprises the following raw materials in parts by weight: astragaloside A 4-7 parts, arctiin 8-12 parts, citrinin 3-6 parts, and perilla lactone 2-4 parts. Experimental results show that taking the traditional Chinese medicine composition for improving heart failure prepared according to this invention has the effects of tonifying heart qi, warming yang and tonifying kidney, promoting blood circulation and detoxifying, and reducing swelling and promoting diuresis, thereby effectively improving cardiac function, inhibiting excessive activation of the RAAS system, reducing myocardial damage and myocardial fibrosis, and significantly alleviating heart failure symptoms. Furthermore, the traditional Chinese medicine composition provided by this invention has precise formulation, few toxic side effects, high safety, and broad application prospects.

The application of a class of N-substituted phenyl-2-pyridone compounds in treating cancer and relieving fibrosis belongs to the technical field of medicine. The compound is an N-substituted phenyl-2-pyridone compound or a pharmaceutical derivative or preparation thereof. The cancer includes one or more of common cancers such as lung cancer, breast cancer, liver cancer, prostate cancer, pancreatic cancer and the like. The fibrosis disease includes one or more of diseases such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, myocardial fibrosis and the like or diseases induced by fibrosis. The drug can be combined with one or more pharmaceutical carriers to form a drug combination. The drug or the pharmaceutical composition thereof can be used alone or in combination with other drugs. The class of N-substituted phenyl-2-pyridone compounds has anticancer efficacy and presents excellent ability to relieve organ and tissue fibrosis, has good safety, and is expected to be developed into a clinical first-line drug.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The present disclosure provides a pharmaceutical composition for regenerating myocardium, inhibiting myocardial fibrosis, or treating cardiac disease comprising a polynucleotide encoding a constitutive active IKK [beta].

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Pannexin1 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to clarify the effect of pan-connexin1 in the cardiac hypertrophy process caused by overload of pressure, the invention provides application of an inhibitor of a targeted Pannexin1 gene in preparation of a medicine for preventing or treating myocardial fibrosis. According to the invention, it is found for the first time that Pannexin1 is an effective target spot for treating myocardial hypertrophy caused by pressure overload, and an expression inhibitor for inhibiting Pannexin1 by targeting the target spot can be used for preparing drugs for treating myocardial hypertrophy caused by pressure overload. Therefore, the invention provides the application of the inhibitor targeting the Pannexin1 gene in preparation of the medicine for preventing or treating the myocardial fibrosis, and a new treatment mode is provided for treatment of the myocardial fibrosis.

The invention discloses application of a serine protease inhibitor A3 in preparation of a medicine for preventing and / or treating heart failure diseases. Experimental results show that the SERPINA3 can improve cardiac function reduction, improve ventricular remodeling, reduce myocardial fibrosis, inhibit proliferation and migration ability of cardiac fibroblasts, inhibit differentiation of the cardiac fibroblasts to myofibroblasts and inhibit extracellular matrix proteins. The serine protease inhibitor A3 can inhibit cardiac fibroblast activation and myocardial fibrosis, and provides a new treatment strategy and means for clinical treatment of intractable heart failure.

The invention discloses a mouse myocardial fibrosis pathological model inducer. The recombinant adeno-associated virus expressing RGS4 can promote the process of myocardial fibrosis of mice by up-regulating the expression level of the RGS4 gene in myocardial tissues after being injected into the heart of the mice in situ, and can be used for inducing a myocardial fibrosis model of the mice. The invention provides a new thought and strategy for constructing a mouse myocardial fibrosis pathological model, and has a wide pharmacological research application prospect.

The invention discloses application of cinnamic acid in preparation of a medicine for preventing or treating myocardial infarction chronic-stage pathological injury, and relates to the technical field of medicines. A coronary artery ligation animal model is used for simulating a chronic-stage pathological injury process after myocardial infarction, the cinnamic acid is subjected to gavage intervention, and various detection methods are used for evaluating the intervention effect of the cinnamic acid, so that the cinnamic acid is proved to have a remarkable curative effect on chronic-stage myocardial fibrosis, ventricular remodeling and heart failure after myocardial infarction for the first time; the invention further provides the application of the cinnamic acid in preparation of the medicine for preventing or treating myocardial infarction chronic-stage pathological injury, and compared with previous researches, the application range of the cinnamic acid is expanded, so that the application research of the cinnamic acid and the research and development of the medicine for myocardial infarction are both of great significance to application research of the cinnamic acid and research and development of the medicine for myocardial infarction.

The application discloses an evaluation and diagnosis system for myocardial fibrosis based on photon CT energy scanning and belongs to the technical field of myocardial fibrosis evaluation. The evaluation and diagnosis system for myocardial fibrosis based on photon CT energy scanning comprises a scanning data acquisition module, a full-automatic heart segmentation module, a biological feature recognition module, a fibrosis region recognition module and a multi-parameter quantitative analysis module. The application solves the problem that the prior art has weak boundary distinguishing ability for myocardium, blood vessels and valves, and is prone to cause segment division deviation. The application realizes automatic and accurate segmentation of left ventricular myocardium, ensures the accuracy of standard 17-segment model division, greatly improves the speed and efficiency of fibrosis region recognition, effectively reduces manual operation intervention, reduces human error, improves the efficiency and accuracy of diagnosis, can comprehensively quantitatively analyze each myocardial segment and output rich key indicators.

The invention discloses application of NINJ1 in treatment of adriamycin-induced myocardial injury, and relates to the field of biological medicine. The NINJ1 is applied to preparation of a medicine for preventing and / or treating adriamycin-induced myocardial injury, and the application comprises the step of achieving the purpose of preventing and / or treating adriamycin-induced myocardial cell injury, cardiac insufficiency, myocardial fibrosis or heart failure by inhibiting expression or activity of NINJ1. Wherein the mode of inhibiting the NINJ1 comprises the use of an NINJ1 inhibitor, the knockout of an NINJ1 gene or the silencing of the NINJ1 gene. The key effect of the NINJ1 in doxorubicin cardiotoxicity is disclosed for the first time, the NINJ1 is determined as a new therapeutic target, a new direction and theoretical basis are provided for development of drugs for preventing and treating doxorubicin cardiotoxicity, and the NINJ1 has important clinical value.

The present application relates to the technical field of medicine, and particularly relates to application of OpiCa1 or a nano-liposome thereof in preparation of a drug for treating and / or preventing myocardial fibrosis related diseases. The present application is found that OpiCa1 and the nano-liposome thereof can inhibit myocardial fibrosis and improve myocardial remodeling in the myocardial remodeling period after myocardial infarction, and have a good antagonistic effect on myocardial infarction and subsequent heart failure. Further transcriptomic analysis shows that in the process of treating myocardial infarction in mice, OpiCa1 and the nano-liposome thereof can inhibit fibrosis and improve myocardial remodeling by possibly participating in extracellular matrix degradation in myocardial remodeling and fibrosis pathways (such as TGF-beta signaling pathway), so as to achieve the purpose of relieving myocardial infarction deterioration.

A pharmaceutical composition comprising a diuretic and at least one additional active ingredient selected from the group consisting of ACE inhibitors, sartans, calcium channel blockers, alpha blockers, and beta blockers, wherein the diuretic is in a first pharmaceutical form that increases its dissolving rate. The invention also relates to the above composition for use in the treatment of a condition selected from heart failure, arterial hypertension, myocardial fibrosis, and cardiac hypertrophy.

The invention belongs to the technical field of biological medicines, and particularly relates to a lactobacillus rhamnosus MF26 and application thereof in prevention and treatment of heart failure. The preservation number of the mouse combined lactobacillus MF26 is CCTCC (China Center for Type Culture Collection) NO: M 20251548, and the preservation institution of the mouse combined lactobacillus MF26 is China Center for Type Culture Collection (CCTCC). The mouse combined lactobacillus MF26 disclosed by the invention can be used for remarkably improving the heart left ventricular diastolic dysfunction of an HFpEF mouse, reducing myocardial fibrosis, relieving blood pressure rise, remarkably improving the intestinal barrier permeability, reducing the body inflammation level and remarkably improving the level of GLP-1 in serum, so that the fasting blood glucose level and the glucose tolerance of the HFpEF mouse are effectively improved. Therefore, the lactobacillus rhamnosus MF26 can be used for preparing medicines or functional foods for preventing, relieving or / and treating ejection fraction retention type heart failure.

The invention relates to the technical field of medicines, in particular to a PCM-OpiCa1 liposome as well as a preparation method and application thereof. According to the invention, PCM is adopted to modify the OpiCa1 nano-liposome, so that the targeting enrichment effect can be achieved, the ability of the OpiCa1 polypeptide drug entering cardiac muscle cells is improved, the targeting property of the nano-liposome can be effectively improved, the drug effect of OpiCa1 can be further improved, and the toxic and side effects can be reduced. The research on modeling and administration of myocardial infarction mice finds that the PCM-OpiCa1 liposome can inhibit myocardial fibrosis and improve myocardial remodeling in the myocardial remodeling period after myocardial infarction, and has a good antagonistic effect on myocardial infarction and subsequent heart failure.

The present invention relates to 5-(4-fluorophenyl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole derivatives of formula (I) as ALK5 inhibitors (transforming growth factor 3 (TGF3) type 1 receptor) for the treatment of fibrosis, such as e.g. pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), hepatic fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis. An example with good activity is e.g. example 5: 2-(dimethylamino)-N-(2-fluoro-5-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H imidazo[1,2-a]imidazol-5-yl)phenyl)acetamide (Formula IA). Pharmacological data is provided: (Table 3)TABLE 3Example NoALK5 pKi2, 9, 10≥9.01, 3, 4, 7, 8, 11, 12, 148.1-8.95, 6, 137.5-8.0

The invention discloses a preparation method of a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of a medicine for preventing and treating hypertrophic cardiomyopathy, and belongs to the technical field of traditional Chinese medicines. The technical problem to be solved is to provide the traditional Chinese medicine for treating dilated cardiomyopathy, atherosclerotic plaque, myocardial fibrosis, ventricular remodeling, senile cardiac metabolic disorder, hypertrophic cardiomyopathy, hypertrophic cardiomyopathy and hypertrophic cardiomyopathy aiming at the defects of the prior art in preparation of medicines for preventing and treating hypertrophic cardiomyopathy. The invention also discloses application of the traditional Chinese medicine composition in preparation of medicines for treating hypertrophic cardiomyopathy, wherein the traditional Chinese medicine composition has the effects of improving cardiac degeneration of mice with myocardial hypertrophy induced by blood constriction. According to the key point of the technical scheme, the invention provides the application of the traditional Chinese medicine composition in preparing the medicine for preventing and treating hypertrophic cardiomyopathy. The traditional Chinese medicine composition comprises the following raw materials: American ginseng, ginseng, astragalus membranaceus, spina date seeds, salvia miltiorrhiza, pseudo-ginseng, fingered citron and mangnolia officinalis.

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Xirp2 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to determine the effect of the actin binding protein Xirp2 in the cardiac hypertrophy process caused by pathological matrix hardness-induced myocardial cell hypertrophy and pressure overload, the invention provides application of an inhibitor of a targeted Xirp2 gene in preparation of a medicine for preventing or treating myocardial fibrosis. The inhibitor is siRNA of which the nucleotide sequence is shown as SEQ ID NO: 1-3 or shRNA of which the nucleotide sequence is shown as SEQ ID NO: 4. The invention finds that Xirp2 is related to myocardial hypertrophy caused by myocardial cell hypertrophy induced by pathological matrix hardness and myocardial hypertrophy caused by pressure overload for the first time, and after expression of Xirp2 is knocked down in vivo and in vitro, myocardial hypertrophy can be relieved. Therefore, the invention develops a new application of the inhibitor targeting the Xirp2 gene, develops a new medicine and a new treatment mode for myocardial fibrosis, and has great significance.